MGI 114: Augmentation of antitumor activity when combined with topotecan

American Journal of Pediatric Hematology/Oncology

Volumn 22, Issue 4, 2000, Pages 306-314

  Weitman, Steven ^a,b   Barrera, Hector ^a   Moore, Rodney ^a   Gonzalez, Cristina ^a   Marty, Jennifer ^a   Hilsenbeck, Susan ^b   MacDonald, John R ^c   Waters, Stephen J ^a   Von Hoff, Daniel ^a  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

HMAF; Illudins; MGI 114; Pediatric oncology; Synergy

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; ILLUDIN S; IROFULVEN; MYCOTOXIN; TOPOTECAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CHILDHOOD CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; MOUSE; NEUROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; INHIBITORY CONCENTRATION 50; MEDULLOBLASTOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SESQUITERPENES; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034456925     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200007000-00006     Document Type: Article

References (25)

1. Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R. Efficacy of HMAF (MGI 114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 1996;14: 161-7.
2. MacDonald JR, Muscoplat CC, Dexter DL, et al. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 1997;57: 279-83.
3. McMorris TC, Kelner MJ, Wang W, Yu J, Estes LA, Taetle R. (Hydroxymethyl) acylfulvene: An illudin derivative with superior antitumor properties. J Nat Prod 1996;59: 896-9.
4. McMorris TC, Yu J, Estes LA, Kelner MJ. Reaction of antitumor hydroxymethylacylfulvene (HMAF) with thiols. Tetrahedron 1997;53: 14579.
5. Kelner MJ, McMorris TC, Taetle R. Preclinical evaluation of illudins as anticancer agents: Basis for selective cytotoxicity. J Natl Cancer Inst 1990;82: 1562-5.
6. Kelner MJ, McMorris TC, Estes L, et al. Characterization of illudin S sensitivity in DNA repair-deficient chinese hamster cells. Biochem Pharmacol 1994;48: 403-9.
7. Kelner MJ, McMorris TC, Estes L, et al. Efficacy of acylfulvene illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: Retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. Cancer Res 1995;55: 4936-40.
8. Woynarowski JM, Napier C, Koester SK, et al. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol 1997;54: 1181-930.
9. Sunderman FW. The influence of zinc on apoptosis. Ann Clin Lab Sci 1995;25: 134.
10. Kelner M, McMorris T, Estes L, Samson K, Bagnell R, Taetle R. Efficacy of MGI 114 (6-hydroxmethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. Eur J Cancer 1998;34: 908-13.
11. Britten CD, Hilsenbeck SG, Eckhardt SG, et al. Enhanced antitumor activity of 6-hyroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 1999;59: 1049-53.
12. Vassal G, Pondarre C, Boland I, et al. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie 1998;80: 271-80.
13. Weitman S, Moore R, Barrera H, Cheung NK, Izbicka E, Von Hoff DD. In vitro antitumor activity of rebeccamycin analog (NSC #655649) against pediatric solid tumors. J Pediatr Hematol Oncol 1998;20: 136.
14. Laska EM, Meisner M, Siegel C. Simple designs and model-free tests for synergy. Biometrics 1994;50: 834-41.
15. Hochberg Y, Tamhane AC. Multiple comparison procedures. New York: J Wiley & Sons, Inc., 1987.
16. Box GEP, Cox DR. Analysis of transformations. J Royal Stat Soc 1964;26: 211-52.
17. Eckhardt SG, Weiss GR, Kraynak M, et al. MGI 114-a novel mushroom-derived cytotoxin: A phase I and pharmacokinetic (PK) study in patients with advanced cancer. Proc Am Assoc Cancer Res 1997;38: 306.
18. Duget M. When helicase and topoisomerase meet! J Cell Sci 1997;110: 1345-50.
19. Bachur NR, Sun PM, Truby CM. Helicase blockade by DNA minor groove binding agents. Proc Am Assoc Cancer Res 1998;39: 305.
20. Moore RM, MacDonald JR, Von Hoff D, Weitman S. Antitumor activity of MGI 114 in combination with DNA helicase inhibitors against pediatric tumor cell lines. Proc Am Assoc Cancer Res 1999;40: 590.
21. Kessel D, Bosmann HB, Lohr R. Camptothecin effects on DNA synthesis in murine leukemia cells. Biochim Biophys Acta 1972;269: 210-6.
22. Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res 1972;32: 2643-50.
23. Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: Evidence for cell cycle-independent toxicity. J Cell Biol 1996;134: 757-70.
24. Traganos F, Seiter K, Feldman E, Halicka HD, Darzynkiewicz Z. Induction of apoptosis by camptothecin and topotecan. Ann NY Acad Sci 1996;803: 101-10.
25. Shao RG, Cao CX, Shimizu T, O’Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997;57: 4029-35.